Showing 1651-1660 of 2314 results for "".
- Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)https://modernod.com/news/oxurion-nv-reports-first-patient-dosed-in-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme/2478228/Oxurion NV reported that the first patient has been dosed in its two-part phase 2 study (“KALAHARI”) evaluating THR-149 for the treatment of DME. THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, a validated VEGF independent target for DME. In a phase 1 st
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher
- Dosing Begins in Moderna’s Late-Stage Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/Moderna announced that patient dosing started in the phase 3 COVE study of its mRNA-based vaccine candidate against the novel coronavirus, sending company shares up as much as 11.3% on Monday. The trial of mRNA-1273 is being conducted in collaboration with the US National Institute of Allergy and
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- National Vision Announces Special Cash Bonus to Front-Line Associates and Doctorshttps://modernod.com/news/national-vision-announces-special-cash-bonus-to-front-line-associates-and-doctors/2478032/National Vision Holdings announced plans to grant a special cash bonus to front-line associates and doctors. A one-time $250 bonus will be given to all patient-facing and customer-facing associates and the company’s network of doctors in recognition of their hard work and dedication toward
- Regeneron Advances Double Antibody Cocktail Into Phase 3 COVID-19 Prevention Studyhttps://modernod.com/news/regeneron-kicks-off-prevention-trial-for-covid-19-antibody-cocktail/2477979/Regeneron Pharmaceuticals announced the start of a phase 3 study investigating the ability of the double antibody cocktail REGN-COV2 to prevent infection among uninfected people who have had close exposure to a COVID-19 patient, according to a FirstWord Pharma report. The company added that REGN-
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (